GlaxoSmithKline Says Advair Shows Edge over Spiriva in COPD

LONDON (Reuters) - GlaxoSmithKline Plc said on Friday that clinical trial results showed its top-seller Advair had an edge over Pfizer Inc's (PFE.N: Quote, Profile, Research) rival product Spiriva in treating patients with the lung disease COPD.